Bisphosphonates and alendronate

Fabad Journal of Pharmaceutical Sciences

Volumn 31, Issue 1, 2006, Pages 31-42

  Karamustafa, Fulya ^a   Çelebi, Nevin ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Adverse effects; Alendronate; Analysis; Bisphosphonates; Pharmacokinetics; Therapeutic use

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CARBON 14; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ABDOMINAL PAIN; BONE DISEASE; BONE METABOLISM; BONE MINERAL; CLINICAL TRIAL; CONSTIPATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGALGIA; ESOPHAGITIS; ESOPHAGUS HEMORRHAGE; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HEMATEMESIS; HUMAN; HYPERCALCEMIA; METASTASIS; MORNING DOSAGE; NAUSEA; NONHUMAN; ODYNOPHAGIA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PH; PHYSICAL CHEMISTRY; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; REFLUX ESOPHAGITIS; REVIEW; STOMACH INJURY; STRUCTURE ACTIVITY RELATION;

EID: 42649132849     PISSN: 13004182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate, Ann Clin Biochem, 38 (6), 608-623, 2001.
2. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor, Am J Physiol, 203 (4), 671-675, 1962.
3. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis, Nature, 20, 901-903, 1966.
4. Francis RM. Bisphosphonates in the treatment of osteoporosis in 1997: a review, Curr Ther Res, 58 (10), 656-678, 1997.
5. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates, Cancer Supp, 88 (12), 2961-2978, 2000.
6. Fleisch H, Russell RGG, Bisaz S, Muhlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo, Eur J Clin Invest, 1, 12-18, 1970.
7. Rosen CJ, Kessenich CR. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases, Drugs, 51 (4), 537-551, 1996.
8. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials, Pain, 78, 157-169, 1998.
9. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption, Adv Drug Del Rev, 42, 175-195, 2000.
10. Van Der Pluijm G, Binderup L, Bramm E, Van Der Wee-Pals L, De Groot H, Binderup E, Lowik C, Papapoulos S. Disodium 1-hydroxy-3-(1-pyrrolidinyl)- propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo, J Bone Miner Res, 7 (8), 981-986, 1992.
11. Berstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase, Arc Biochem Biophy, 373 (1), 231-241, 2000.
12. Fernandez D, Vega D. Head-to-head dimers in the zwitterion of 1-hydroxy-1-phosphono-3-(1-piperidino) propylidene-1-phosphonate (PHPBP), Acta Crystall C, 59, 661-663, 2003.
13. Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y, Matsumura T. Effect of a newly developed bisphosphonate, YM529, on osteolytic bone metastases in nude mice, Int J Cancer, 77 (2), 279-285, 1998.
14. Nishida S, Fujii Y, Yoshioka S, Kikuichi S, Tsubaki M, Irimajiri K. A new bisphosphonate, YM529, induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK, Life Sci, 73, 2655-2664, 2003.
15. Nagashima M, Sakai A, Uchida S, Tanaka S, Tanaka M, Nakamura T. Bisphosphonate (YM529) delays the repair of cortical bone defect after drill-hole injury by reducing terminal differentiation of osteoblasts in the mouse femur, Bone, 36, 502-511, 2005.
16. Hiraga T, Tanakas S, Yamamoto M, Nakajima T, Ozawa H. Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor, Bone, 18 (1), 1-7, 1996.
17. Nagao Y, Ishitobi Y, Kinoshita H, Fukushima S, Kawashima H. YM175, a new bisphosphonate, increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity, Biochem Biophy Res Com, 180 (3), 1172-1178, 1991.
18. Compston JE. Fortnightly review: the therapeutic use of bisphosphonates, BMJ, 309, 711-715, 1994.
19. Jeal W, Barradell LB, Mctavish D. Alendronate, a review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis, Drugs, 53 (3), 415-434, 1997.
20. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 1535-1541, 1996.
21. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action, J Clin Invest, 97, 2692-2696, 1996.
22. Ylitalo R. Bisphosphonates and atherosclerosis, Gen Pharmacol, 35, 287-296, 2002.
23. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma, N Engl J Med, 334 (8), 488-493, 1996.
24. Fleisch H. Bisphosphonates, pharmacology and use in the treatment of tumour-induced hypercalcemic and metastatic bone disease, Drugs, 42 (6), 919-944, 1991.
25. Mccloskey EV, Maclennan ICM, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults, Br J Haematol, 100, 317-325, 1998.
26. Shipman CM, Rogers MJ, Apperley JF, Graham G, Russell G, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity, Br J Haematol, 98, 665-672, 1997.
27. Hirago T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases, Cancer Res, 61, 4418-4424, 2001.
28. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease, J Nucl Med, 19, 270-275, 1978.
29. Russell RGG, Rogers MJ. Bisphosponates: from the laboratory to the clinic and back again, Bone, 25 (1), 97-106, 1999.
30. Orcel P, Beaudreuil J. Bisphosphonates in bone diseases other than osteoporosis, Joint Bone Spine, 69, 19-27, 2002.
31. Geddes AD, D'souza SM, Ebetino FH, Ibbotson KJ. Bisphosphonates: structure-activity relationships and therapeutic implications, Bone Miner Res, 8, 265-306, 1994.
32. Green J, Clay V, Richardson J, Hassan IF. The effect of zoledronate and pamidronate on the intestinal permeability barrier in vitro and in vivo, Int J Pharm, 153, 59-66, 1997.
33. Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function, J Bone Min Res, 12 (6), 869-879, 1997.
34. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones, Bone, 19 (3), 281-290, 1996.
35. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action, alendronate localization in rat bone and effects on osteoclast ultrastructure, J Clin Invest, 88, 2095-2105, 1991.
36. Hughes DE, Macdonald BR, Russell RGG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow, J Clin Invest, 83, 1930-1935, 1989.
37. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts, J Clin Invest, 91, 2004-2011, 1993.
38. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures, Bone, 18 (1), 9-14, 1996.
39. Yu X, Scholler J, Foged NT. Interaction between effects of parathyroid hormone and bisphosphonates on regulation of osteoclast activity by the osteoblast-like cell line UMR-106, Bone, 19 (4), 339-345, 1996.
40. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties, Bone, 18 (2), 75-85, 1996.
41. Kwong E, Chiu AMY, Mcclintock SA, Cotton ML. HPLC analysis of an amino bisphosphonate in pharmaceutical formulations using postcolumn derivatization and fluorescence detection, J Chromatog Sci, 28, 563-566, 1990.
42. Physicians' Desk Reference PDR. 59th ed. Thomson, Montvale, NJ, 1997, 2005.
43. De Marco J, Biffar SE, Reed DG, Brooks MA. The determination of 4-amino-1hydroxybutane-1,1-diphosphonic acid monosodium salt trihydrate in pharmaceutical dosage forms by high-performance liquid chromatography, J Pharm Biomed Anal, 7 (12), 1719-1727, 1989.
44. Physicians' Desk Reference PDR, 58th ed. Thomson. Montvale, NJ, 1986-1992, 2004
45. Lin JL, Chen I-W, Deluna FA. On the absorption of alendronate in rats, J Pharm Sci, 83 (12), 1741-1746, 1994.
46. Bone HG, Adami S, Rizzoli R, Favus M, Ross PD, Santora A, Prahalada S, Daifotis A, Orloff J, Yates J. Weekly administration of alendronate: rationale and plan for clinical assessment, Clin Ther, 22 (1), 15-28, 2000.
47. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriuguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC II, Lombardi A, Shah RV, Hirsch LJ, Karpf DB. Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, N Engl J Med, 333 (22), 1437-1443, 1995.
48. Sharpe M, Noble S, Spencer CM. Alendronate an update of its use in osteoporosis, Drugs, 61 (7), 999-1039, 2001.
49. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice M-P, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis, N Engl J Med, 339 (5), 292-299, 1998.
50. Lin JH, Chen I-W, Deluna FA, Hichens M. Role of calcium in plasma protein binding and renal handling of alendronate in hypo-and hypercalcemic rats, J Pharmacol Exp Ther, 267 (2), 670-675, 1993.
51. Kirk JK, Spangler JG. Alendronate: a bisphosphonate for treatment of osteoporosis, Clin Pharmacol, 54 (6) 2053-2060, 1996.
52. Lainesse A, Ozalp Y, Wong H, Alpan RS. Bioequivalence studies on bisphosphonates: the example of alendronate, Arzneim-Forsch./Drug Res, 54 (9a), 569-572, 2004.
53. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells, Scand J Rheumatol, 27, 38-41, 1998.
54. Opas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A. Alendronate inhibition of protein-tyrosine-phosphatase-meg 1, Biochem Pharmacol, 54, 721-727, 1997.
55. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate, Clin Pharmacokinet, 36 (5), 315-328, 1999.
56. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG. Studies of the oral bioavailability of alendronate, Clin Pharmacol Ther, 58 (3), 288-298, 1995.
57. Lombardi A. Treatment of Paget's disease of bone with alendronate, Bone, 24 (5), 59S-61S, 1999.
58. Lin JH, Duggan DE, Chen I-W, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals, Drug Metab Dispos, 19 (5), 926-932, 1991.
59. Lin JH, Chen I-W, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats, Drug Metab Dispos, 20 (4), 473-478, 1992.
60. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, Mccloskey EV, Beneton MNC, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM., Rogers SR, Porras AG. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis, J Bone Mineral Res, 12 (10), 1700-1707, 1997.
61. Cocquyt V, Kline WF, Gertz BJ, Van Belle SJP, Holland SD, Desmet M, Quan H, Vyas KP, Zhang KE, De Gr_ve J, Porras AG. Pharmacokinetics of intravenous alendronate, J Clin Pharmacol, 39, 385-393, 1999.
62. Lin JH, Chen I-W, Deluna FA, Hichens M. Renal handling of alendronate in rats, an uncharacterized renal transport system, Drug Metab Dispos, 20 (4), 608-613, 1992.
63. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK. Esophagitis associated with the use of alendronate, N Engl J Med, 335 (14), 1016-1021, 1996.
64. Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs-comparison of alendronate and aspirin, Am J Gastroenterol, 92 (8), 1322-1325, 1997.
65. Lowe CE, Depew WT, Vanner SJ, Paterson WG, Meddings JB. Upper gastrointestinal toxicity of alendronate, Am J Gastroenterol, 95 (3), 634-640, 2000.
66. Graham DY, Malaty HM. Drug-induced gastric ulcers are caused by more than just NSAIDS: alendronate gastric ulcers, Gastroenterol, 114, AGA Abstracts, A138, 1998.
67. Merck & Co. Alendronate prescribing information. West Point. Pennsylvania, USA, Sept 1995.
68. Lanza FL. The effects of amino-versus alkylbisphosphonates on the healing of aspirin-induced stomach erosions in healthy subjects, Am J Gastroenterol, 91 (9), 1916, 1996.
69. Lanza F, Schwartz H, Sahba B, Malaty HM, Musliner T, Reyes R, Quan H, Raham DY. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae, Am J Gastroenterol, 95 (11), 3112-3117, 2000.
70. Peter CP, Handt LK, Smith SM. Esophageal irritation due to alendronate sodium tablets: possible mechanisms, Dig Dis Sci, 43 (9), 1998-2002, 1998.
71. Krasagakis K, Krüger-Krasagakis S, Ioannidou D, Tosca A. Chronic erosive and ulcerative oral lesions caused by incorrect administration of alendronate, J Am Acad Dermatol, 50 (4), 651-652, 2004.
72. Tsun EC, Heck AM. Intermittent dosing of alendronate, Ann Pharmacother, 35, 1471-1475, 2001.
73. Lanza F. Bisphosphonate mucosal injury-the end of the story?, Dig Liver Dis, 35, 67-70, 2003.
74. Kuljanin J, Jankovi_ I, Nedeljkovi_ J, Prstojevi_ D, Marinkovi_ V. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe (III) ions, J Pharm Biomed Anal, 28, 1215-1220, 2002.
75. Oin X-Z, Tsai EW, Sakuma T, Ip DP. Pharmaceutical application of liquid chromatography-mass spectrometry II ion chromatography-ion spray mass spectrometric characterization of alendronate, J Chromatog A, 686, 205-212, 1994.
76. Thompson R, Grinberg N, Perpali H, Bicker G, Tway P. Separation of organophosphonates by ion chromatography with indirect photometric detection, J Liq Chromatog, 17 (11), 2511-2531, 1994.
77. Tsai EW, Chamberlin SD, Forsyth RJ, Bell C, Ip DP, Brooks MA. Determination of bisphosphonate drugs in pharmaceutical dosage formulations by ion chromatography with indirect UV detection, J Pharm Biomed Anal, 12 (8), 983-991, 1994.
78. Tsai EW, Ip DP, Brooks MA. Determination of alendronate in pharmaceutical dosage formulations by ion chromatography with conductivity detection, J Chromatog, 596, 217-224, 1992.
79. Tsai EW, Singh MM, Lu HH, Ip DP, Brooks MA. Application of capillary electrophoresis to pharmaceutical analysis. Determination of alendronate in dosage forms, J Chromatog, 626, 245-250, 1992.
80. Reed DG, Martin GP, Konieczny JM, Brooks MA. The determination of alendronate sodium in tablets by inductively coupled plasma (ICP), J Pharm Biomed Anal, 13, 1055-1058, 1995.
81. Han Y-HR, Qin X-Z. Determination of alendronate sodium by ion chromatography with refractive index detection, J Chromatog A, 719, 345-352, 1996.
82. Kline WF, Matuszewski BK. Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection, J Chromatog, 583, 183-193, 1992.
83. Kline WF, Matuszewski BK, Bayne WF. Determination of 4-amino-1- hydroxybutane-1,1-bisphosphonic acid in urine by automated precolumn derivatization with 2,3-naphthalene dicarboxyaldehyde and high-performance liquid chromatography with fluorescence detection, J Chromatog, 534, 139-149, 1990.
84. Al Deeb SK, Hamdan II, Al Najjar SM. Spectroscopic and HPLC methods for the determination of alendronate in tablets and urine, Talanta, 64 (3), 695-702, 2004.
85. Pt_ek P, Kl_ma J, Macek J. Determination of alendronate in human urine as 9-fluorenylmethyl derivative by high performance liquid chromatography, J Chromatog B, 767, 111-116, 2002.
86. Ostovi_ D, Stelmach C, Hulshizer B. Formation of chromophoric complex between alendronate and copper (II) ions, Pharm Res, 10 (3), 470-474, 1993.
87. Razak OA, Belal SF, Bedair MM, Haggag RS. The utilization of copper (II) phosphate for the anodic stripping voltametric assay of alendronate sodium, desferrioxamine mesylate and lisinopril, Talanta, 59, 1061-1069, 2003.
88. Kova_evi_ M, Gartner A, Novi_ M. Determination of bisphosphonates by ion chromatography - inductively coupled plasma mass spectrometry, J Chromatog A, 1039, 77-82, 2004.
89. Karamustafa F. Development of a microemulsion formulation of alendronate and evaluation of its transport through Caco-2 cells [dissertation]. Ankara (Turkey): Gazi University Institute of Health Sciences; 2005.
90. OMMATY R. Vademecum Modern İlaç Rehberi+ATC Index. 27th ed. Ankara; 2005.
91. Karamustafa F, Çilek A, Çelebi N. Development of a microemulsion formulation of improved oral delivery of alendronate. Pharmaceutical Sciences Fair & Exhibition. Nice, France: June 12-17, 2005.